159 related articles for article (PubMed ID: 22708415)
1. [Bronchial asthma: new prospects in therapy].
Ter Arkh; 2012; 84(3):5-11. PubMed ID: 22708415
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
[TBL] [Abstract][Full Text] [Related]
3. Treating atopic asthma with the anti-IgE monoclonal antibody.
D'Amato G
Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in asthma: an update on recent developments.
Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
[TBL] [Abstract][Full Text] [Related]
6. Anti-IgE for asthma in inner-city children.
Geraci C; Longo G
N Engl J Med; 2011 Jun; 364(26):2557; author reply 2557-8. PubMed ID: 21714663
[No Abstract] [Full Text] [Related]
7. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
8. [Programs for continuing medical education: A session; 7. Current topics of asthma treatment--anti-IgE therapy].
Adachi M; Tanaka A
Nihon Naika Gakkai Zasshi; 2012 Mar; 101(3):689-93. PubMed ID: 22620037
[No Abstract] [Full Text] [Related]
9. Omalizumab beyond asthma.
Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
[TBL] [Abstract][Full Text] [Related]
10. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
11. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
12. [Anti-IgE therapy in persistent allergic asthma].
Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
[TBL] [Abstract][Full Text] [Related]
13. [The add-on effect of omalizumab on patients with uncontrolled bronchial asthma].
Minami Y; Endo S; Okumur S; Sasaki T; Yamamoto Y; Ogasa T; Osanai S; Ohsaki Y
Nihon Kokyuki Gakkai Zasshi; 2011 Nov; 49(11):793-9. PubMed ID: 22171481
[TBL] [Abstract][Full Text] [Related]
14. Anti-IgE therapy: clinical utility and mechanistic insights.
Logsdon SL; Oettgen HC
Curr Top Microbiol Immunol; 2015; 388():39-61. PubMed ID: 25553794
[TBL] [Abstract][Full Text] [Related]
15. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
16. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
[TBL] [Abstract][Full Text] [Related]
17. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation.
Fahy JV
J Allergy Clin Immunol; 2006 Jun; 117(6):1230-2. PubMed ID: 16750979
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities.
Rizk C; Ring A; Santucci S; MacLusky I; Karsh J; Yang WH
Ann Allergy Asthma Immunol; 2012 Sep; 109(3):222-3. PubMed ID: 22920081
[No Abstract] [Full Text] [Related]
19. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
Moss RB
Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for severe allergic asthma: 7 years and open questions.
Solèr M
Respiration; 2014; 88(2):158-61. PubMed ID: 24818580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
